M2 Pharma - Therapy Areas

CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation

4 November 2026 - Swedish precision oncology company CHOSA Oncology AB (Spotlight Stock Market: CHOSA) said on Wednesday it has signed an agreement with a CLIA-certified laboratory to develop and vali...

BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma

4 November 2026 - Oncology company BeOne Medicines Ltd (Nasdaq: ONC) (HKEX: 06160) (SSE: 688235) reported on Wednesday that it has received US Food and Drug Administration (FDA) Priority Review for it...

Pentixapharm advances preparationsfor Phase 3 PANDA study

4 November 2026 - Biotechnology company Pentixapharm Holding AG (Frankfurt Prime Standard: PTP) on Wednesday reported further progress towards its pivotal Phase 3 PANDA study, with US ethics approval ...

CStone and Kimia Therapeutics collaborate to advance oncology drug candidate

4 November 2026 - Chinese biopharmaceutical company CStone Pharmaceuticals (HKEX:2616) announced on Tuesday that it has entered into a clinical collaboration agreement with US-based Kimia Therapeutics...

Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia

3 November 2026 - Swedish oncology-focused development company Vivesto AB (STO:VIVE) said on Tuesday that it has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) f...

Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial

3 November 2026 - Clinical-stage biotech company Lytix Biopharma ASA (Euronext Growth Oslo:LYTIX) announced on Tuesday that its Phase II NeoLIPA study evaluating ruxotemitide in combination with pembr...